natgillin/translations-raw huggingface dataset:
When PREVYMIS is co-administered with cyclosporine, dabigatran is contraindicated.
Če se zdravilo PREVYMIS uporablja skupaj s ciklosporinom, je uporaba dabigatrana kontraindicirana.
What you need to know before you take PREVYMIS
Kaj morate vedeti, preden boste vzeli zdravilo PREVYMIS
Letermovir may decrease the plasma concentrations of warfarin.
Letermovir lahko zmanjša plazemske koncentracije varfarina.
Yellow oval tablet of dimensions 16.5 mm x 8.5 mm, debossed with “591” on one side and MSD logo on the other side.
PREVYMIS 240 mg filmsko obložene tablete Rumena, ovalna tableta, velikosti 16,5 mm x 8,5 mm, z vtisnjeno oznako “591” na eni in logotipom MSD na drugi strani.
PREVYMIS 240 mg sterile concentrate letermovir
PREVYMIS 240 mg koncentrat za raztopino za infundiranje letermovir
mycophenolate mofetil (1 g single dose)/ letermovir (480 mg daily)
mofetilmikofenolat (1 g enkratni odmerek)/letermovir (480 mg dnevno)
CMV DNAemia warranting anti-CMV PET
CMV DNA-emija, ki je zahtevala PET proti CMV 52 (16,0)
(600 mg once daily PO)/ letermovir (480 mg once daily PO)
(600 mg enkrat dnevno p.o.)/ letermovir (480 enkrat dnevno p.o.)
(OATP1B1/3 inhibition)
(zaviranje OATP1B1/3)
tacrolimus (5 mg single dose)/ letermovir (480 mg daily)
takrolimus (5 mg enkratni odmerek)/letermovir (480 mg dnevno)
• diarrhoea
• bruhanje
Medicinal products transported by P-gp in the intestine Letermovir is an inducer of intestinal P-gp.
Zdravila, ki se v črevesu prenašajo s P-gp
Modafinil may decrease plasma concentrations of letermovir.
Modafinil lahko zmanjša plazemske koncentracije letermovirja.
fluvastatin, pravastatin
izpuščaj ali koprivnica, srbenje, otekanje
PREVYMIS 480 mg sterile concentrate letermovir
PREVYMIS 480 mg koncentrat za raztopino za infundiranje letermovir
Nevirapine may decrease plasma concentrations of letermovir.
Nevirapin lahko zmanjša plazemske koncentracije letermovirja.
Bosentan may decrease plasma concentrations of letermovir.
Bosentan lahko zmanjša plazemske koncentracije letermovirja.
Co-administration of PREVYMIS and etravirine is not recommended.
Sočasna uporaba zdravila PREVYMIS in etravirina ni priporočljiva.
Nafcillin may decrease plasma concentrations of letermovir.
Nafcilin lahko zmanjša plazemske koncentracije letermovirja.
If you are breast-feeding or are planning to breast-feed, tell your doctor before taking this medicine.
Če dojite ali nameravate dojiti, o tem obvestite zdravnika, preden vzamete to zdravilo.
In rats, maternal toxicity (including decrease in body weight gain) was noted at 250 mg/kg/day (approximately 11-fold the AUC at the RHD); in the offspring, decreased foetal weight with delayed ossification, slightly oedematous foetuses, and increased incidence of shortened umbilical cords and of variations and malformations in the vertebrae, ribs, and pelvis were observed.
Pri mladičih so opazili manjšo telesno maso plodov z zapoznelo osifikacijo, rahlo edematozne plodove in večjo pojavnost skrajšane popkovnice ter variacij in malformacij vretenc, reber in medenice.
Microcrystalline cellulose (E460), croscarmellose sodium (E468), povidone (E1201), colloidal anhydrous silica (E551), magnesium stearate (E470b).
Jedro tablete mikrokristalna celuloza (E460), premreženi natrijev karmelozat (E468), povidon (E1201), brezvodni koloidni silicijev dioksid (E551), magnezijev stearat (E470b) Filmska obloga laktoza monohidrat, hipromeloza (E464), titanov dioksid (E171), triacetin (E1518), rumeni železov oksid (E172), rdeči železov oksid (le v 480 mg tabletah) (E172), karnauba vosek (E903)
Outer carton for 240 mg concentrate for solution for infusion
Škatla za 240 mg koncentrat za raztopino za infundiranje
Etravirine may decrease plasma concentrations of letermovir.
Etravirin lahko zmanjša plazemske koncentracije letermovirja.
PREVYMIS is not recommended in pregnancy.
Uporaba zdravila PREVYMIS med nosečnostjo ni priporočljiva.
Outer carton for 480 mg concentrate for solution for infusion
Škatla za 480 mg koncentrat za raztopino za infundiranje
Therefore, the clinical consequences of drug interactions for letermovir will be dependent on which letermovir regimen is used and whether or not letermovir is combined with cyclosporine.
Zato so klinične posledice interakcij letermovirja odvisne od režima uporabe letermovirja in ali se letermovir uporablja v kombinaciji s ciklosporinom ali ne. - Pri sočasni uporabi ciklosporina in letermovirja lahko pride do izrazitejših ali dodatnih učinkov kot pri uporabi letermovirja samega (glejte preglednico 1).
PREVYMIS 240 mg film-coated tablets letermovir
PREVYMIS 240 mg filmsko obložene tablete letermovir
PREVYMIS 480 mg film-coated tablets letermovir
PREVYMIS 480 mg filmsko obložene tablete letermovir
Outer carton for 240 mg film-coated tablets
Pretisni omot za 240 mg filmsko obložene tablete
Letermovir may decrease the plasma concentrations of phenytoin.
Letermovir lahko zmanjša plazemske koncentracije fenitoina.
Antivirals acyclovir (400 mg single dose)/ letermovir (480 mg daily)
Protivirusna zdravila aciklovir (400 mg enkratni odmerek)/letermovir (480 mg dnevno)
Although not studied, when PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in atorvastatin plasma concentrations is expected to be greater than with PREVYMIS alone.
Pri sočasni uporabi zdravila PREVYMIS in ciklosporina se pričakuje, da se bo plazemska koncentracija atorvastatina povečala v večjem obsegu, kot pri uporabi zdravila PREVYMIS samega, čeprav tega niso raziskali.
PREVYMIS contains cyclodextrin
Zdravilo PREVYMIS vsebuje ciklodekstrin
Frequent monitoring of International Normalised Ratio (INR) should be performed when warfarin is coadministered with PREVYMIS treatment Monitoring is recommended the first 2 weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir or immunosuppressant.
Spremljanje je priporočljivo prva 2 tedna po začetku ali koncu uporabe letermovirja, pa tudi po spremembi poti uporabe letermovirja ali zamenjavi zdravila za zaviranje imunske odzivnosti.
Thioridazine may decrease plasma concentrations of letermovir.
Tioridazin lahko zmanjša plazemske koncentracije letermovirja.
• Norepinephrine bitartrate
• noradrenalinijev bitartrat
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU
Efavirenz may decrease plasma concentrations of letermovir.
Efavirenz lahko zmanjša plazemske koncentracije letermovirja.
The 480 mg tablets are packaged into a carton containing four (4) cardboard cards, each containing a 7-count Polyamide/Aluminium/PVC - Aluminium blister card for a total of 28 tablets.
480 mg tablete so pakirane v škatlo, ki vsebuje štiri (4) kartonske ovitke.
Co-administration of PREVYMIS and nafcillin is not recommended.
Sočasna uporaba zdravila PREVYMIS in nafcilina ni priporočljiva.
The diluted solution should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.
Kadar raztopina in vsebnik to omogočata, morate razredčeno raztopino pred uporabo pregledati glede prisotnosti delcev in spremembe barve.
*Refer to the prescribing information to confirm compatibility of simultaneous co-administration.
*Za potrditev kompatibilnosti pri sočasni uporabi glejte povzetke glavnih značilnosti zdravila.
Outer carton for 480 mg film-coated tablets
Pretisni omot za 480 mg filmsko obložene tablete
Blister for 240 mg film-coated tablets
Škatla za 240 mg filmsko obložene tablete
No maternal or developmental effects were noted at the dose of 50 mg/kg/day (approximately 2.5-fold the AUC at the RHD).
Pri odmerku 50 mg/kg/dan (približno 2,5-kratna vrednost AUC pri uporabi priporočenega odmerka za človeka) niso opazili učinkov pri samicah ali učinkov na razvoj.
The 240 mg tablets are packaged into a carton containing four (4) cardboard cards, each containing a 7-count Polyamide/Aluminium/PVC - Aluminium blister card for a total of 28 tablets.
240 mg tablete so pakirane v škatlo, ki vsebuje štiri (4) kartonske ovitke.
Blister for 480 mg film-coated tablets
Škatla za 480 mg filmsko obložene tablete
PREVYMIS contains lactose
Zdravilo PREVYMIS vsebuje laktozo
Phenytoin may decrease plasma concentrations of letermovir.
Fenitoin lahko zmanjša plazemske koncentracije letermovirja.
Intravenous use after dilution.
uporabo razredčiti.
Letermovir may increase statin plasma concentrations.
Letermovir lahko poveča plazemske koncentracijo statinov.
• Ganciclovir sodium
• natrijev ganciklovirat
Subjects received CMV DNA monitoring weekly until post-transplant week 14 and then bi-weekly until post-transplant week 24, with initiation of standard-of-care CMV pre-emptive therapy if CMV DNAemia was considered clinically significant.
Vrednost CMV DNA so pri preiskovancih do 14. tedna po presaditvi spremljali enkrat na teden, do 24. tedna po presaditvi pa nato dvakrat na teden.
Reproduction
Dojenje
Contains sodium and cyclodextrin.. See package leaflet for further information.
Vsebuje natrij in ciklodekstrin.
Do not take PREVYMIS if:
Ne jemljite zdravila PREVYMIS:
Sodium hydroxide (E524) Water for injections
6.1 Seznam pomožnih snovi hidroksipropilbetadeks (ciklodekstrin) natrijev klorid natrijev hidroksid (E524)
--¹ not less than 10E6.0 CCID50
--¹ ne manj kot 10E6.0 CCID50
1 oral applicator
1 peroralni aplikator
1 glass container + 1 oral applicator + 1 transfer adapter
1 stekleni vsebnik + 1 peroralni aplikator + 1 nastavek za prenos
1 squeezable tube multi-monodose (5 single dose) squeezable tube (polyethylene) presentation connected by a bar
Komplet več enoodmernih stisljivih tub (polietilen) (5 posameznih odmerkov), ki so povezane s ploščico
Therefore, patients must be monitored closely.
Zato morate bolnike skrbno nadzorovati.
No interaction studies have been performed.
Interakcijskih študij niso izvedli.
1 mg corresponds to 18.2 EAU*.
1 mg ustreza 18,2 EAU*.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Tega zdravila ne smete mešati z drugimi zdravili razen s tistimi, ki so omenjena v poglavju 6.6.
This leaflet was last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano {MM/LLLL}
It will be given once a day, for up to 7 days.
Zdravilo boste prejemali enkrat na dan do 7 dni.
• swelling of the face, lips, tongue or throat
• otekanje obraza, ustnic, jezika ali grla
Tell your doctor immediately if you notice any of the following as you may need to stop treatment:
Svojega zdravnika nemudoma obvestite, če opazite karkoli od naslednjega, saj boste morda morali prekiniti zdravljenje:
These may be the first signs that a severe allergic reaction is happening.
To so lahko prvi znaki, da se je pri vas huda alergijska reakcija razvila.
As a protein the dose for the infant is expected to be very low.
Glede na proteinsko naravo, se pričakuje, da je odmerek za dojenčka zelo nizek.
These are rare (may affect up to 1 in 1,000 people).
Ti znaki so redki (lahko prizadenejo do 1 od 1.000 bolnikov).
Date of latest renewal: 23 February 2006
Datum zadnjega podaljšanja dovoljenja za promet: 23. februar 2006
Fasturtec is not directly effective in the treatment of these abnormalities.
Fasturtec ni neposredno učinkovit pri zdravljenju teh anomalij.
It is not known whether the chance of developing an allergic reaction is increased if treatment with Fasturtec is repeated.
Ni znano, če je možnost razvoja alergijskih reakcij povečana, če se zdravljenje z zdravilom Fasturtec ponovi.
The following information is intended for healthcare professionals only: See section 3 “How to use Fasturtec” and practical information on preparation and handling given below.
Naslednje informacije so namenjene samo zdravstvenemu osebju: Glejte poglavje 3 "Kako uporabljati zdravilo Fasturtec" in navodila za pripravo in ravnanje spodaj.
Your treatment with Fasturtec may need to be stopped, and you may need further treatment.
Zdravljenje z zdravilom Fasturtec bo morda treba prekiniti in morda boste potrebovali dodatno zdravljenje.
Special patient populations
Posebna populacija bolnikov
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Do not use this medicine if you notice that the solution is unclear and/or contains particles.
Ne uporabljajte tega zdravila, če opazite, da raztopina ni bistra ali da vsebuje delce.
After reconstitution or dilution an immediate use is recommended.
Po rekonstituciji ali redčenju priporočamo takojšnjo uporabo.
Clearance is increased (ca. 35%) in children and adolescents compared to adults, resulting in a lower systemic exposure.
Očistek pri otrocih in mladostnikih je v primerjavi z odraslimi povečan za približno 35%, kar se kaže v nižji sistemski izpostavljenosti.
Your dose will be calculated according to your body weight.
Vaš odmerek bodo izračunali na osnovi telesne mase.
Frequency not known (frequency cannot be estimated from the available data) - involuntary muscle movements (muscle contraction involuntary).
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov) - nehoteni mišični gibi (nehotena kontrakcija mišic).
Safety results on 246 patients were consistent with the adverse events profile in the overall population.
Rezultati o varnosti pri 246 bolnikih so se skladali s profilom neželenih učinkov v splošni populaciji.
* Anaphylactic shock including potential fatal outcome ** From post-marketing experience + Uncommon G3/4 ++ Common G3/4
* Anafilaktični šok, vključno s potencialnim smrtnim izidom ** Izkušnje v obdobju trženja + Občasni G3/4 ++ Pogosti G3/4
Frequencies are defined using the following MedDRA convention as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Navedba pogostnosti neželenih učinkov po MeDRA klasifikaciji: zelo pogosti (1/10); pogosti (1/100 to <1/10); občasni (1/1,000 to <1/100), redki (1/10,000 to <1/1,000); zelo redki (<1/10,000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
- Convulsion**
- konvulzije**
Fasturtec is injected slowly into a vein, which should take about 30 minutes.
Fasturtec vam bodo počasi injicirali v veno, kar bo trajalo približno 30 minut.
Sample handling:
Ravnanje z vzorci:
Fasturtec will be administered at the same time as other medicines that may also cause side effects.
Fasturtec boste prejemali sočasno kot druga zdravila, ki tudi lahko povzročijo neželene učinke.
No filter should be used for infusion.
Pri infuziji ne smete uporabljati filtra.
9 SPECIAL STORAGE CONDITIONS Store in a refrigerator
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 23 February 2001
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 23. februar 2001
Rasburicase is a protein, and therefore: 1) not expected to bind to proteins, 2) expected that metabolic degradation will follow the pathways of other proteins, i.e. peptide hydrolysis, 3) unlikely to be candidate for drug-drug interactions.
Razburikaza je beljakovina, zato: 1) ne pričakujemo, da se bo vezala na beljakovine, 2) pričakujemo, da se bo metabolno razkrajala po isti poti kot ostale beljakovine, tj. s hidrolizo peptidov in 3) ni verjetno, da bi prišlo do interakcij z drugimi zdravili.
Blood must be collected into pre-chilled tubes containing heparin anticoagulant.
Kri morate zbrati v vnaprej ohlajene epruvete, ki vsebujejo heparin kot antikoagulant.
The safety results of patients treated with Fasturtec in Study EFC4978 were consistent with the adverse events profile observed in previous clinical studies with predominantly paediatric patients.
Rezultati varnosti bolnikov, ki so prejemali zdravilo Fasturtec v študiji EFC4978, so bili skladni s profilom neželenih učinkov opaženih v prejšnjih kliničnih študijah s pretežno pediatričnimi bolniki.
- Severe hypersensitivity reactions
- hude preobčutljivostne reakcije
Your doctor may also test your blood to make sure that you do not develop any blood disorders.
Vaš zdravnik vam bo lahko opravil krvne preiskave tudi z namenom izključitve razvoja krvnih bolezni.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sprostitev serije.
If you are given more Fasturtec than you should be If it does occur, the doctor will closely monitor the effects on your red blood cells and treat any symptoms that follow.
Če ste uporabili večji odmerek zdravila Fasturtec, kot bi smeli V primeru, da se to zgodi, bo zdravnik pazljivo nadziral vpliv zdravila na vaše rdeče krvne celice in zdravil morebitne simptome.
Pharmacotherapeutic group: Detoxifying agents for antineoplastic treatment, ATC code: V03AF07.
Farmakoterapevtska skupina: Zdravila za zaščito organizma pred toksičnostjo citostatikov, oznaka ATC: V03AF07.
Efficacy results on 229 evaluable patients showed an overall response rate (normalization of plasma uric acid levels) of 96.1%.
Rezultati o učinkovitosti pri 229 ocenljivih bolnikih so pokazali celoten delež odziva (normalizacijo koncentracije sečne kisline v plazmi) 96,1 %.
Because teratogenic effects of rasburicase cannot be ruled out, Fasturtec should only be used during pregnancy if strictly necessary.
Teratogenih učinkov razburikaze ni moč izključiti, zato naj se zdravilo Fasturtec v nosečnosti uporablja le, če je to nujno potrebno.
What Fasturtec is and what it is used for
Kaj je zdravilo Fasturtec in za kaj ga uporabljamo
- Diarrhoea + - Vomiting++ - Nausea++
- driska + - bruhanje++ - slabost++
• difficulty in breathing or swallowing
• težave pri dihanju ali požiranju
Sanofi Chimie Route d'Avignon 30390 Aramon France
Sanofi Chimie Route d'Avignon 30390 Aramon Francija
However, the in-use stability has been demonstrated for 24 hours between +2°C and 8°C.
Kljub temu so dokazali, da je pripravljena raztopina stabilna 24 ur pri temperaturi med 2 °C in 8 °C.
- Muscle contraction involuntary**
- nehotena kontrakcija mišic**
Pregnancy and breast-feeding Tell your doctor if you are, or think you may be pregnant, or if you are breast-feeding.
Nosečnost in dojenje Obvestite svojega zdravnika če ste ali mislite, da ste noseči ali čedojite.
Therefore the diluted solution should be infused immediately.
Zato morate razredčeno raztopino uporabiti takoj.
- Bronchospasm - Rhinitis
- bronhospazem - rinitis
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
During treatment with Fasturtec, the advantage of breastfeeding should be weighted against the potential risk for the infant.
Med zdravljenjem z zdravilom Fasturtec je potrebno preceniti prednost dojenja v primerjavi z možnim tveganjem za dojenčka.
Other medicines and Fasturtec
Druga zdravila in zdravilo Fasturtec
In adults (≥ the age of 18 years), age, gender, baseline liver enzymes and creatinine clearance did not impact the pharmacokinetics of rasburicase.
Pri odrasih (starejših od 18 let), starost, spol, bazalni jetrni encimi in očistek kreatinina niso vplivali na farmakokinetiko razburikaze.
*One enzyme activity unit (EAU) corresponds to the enzyme activity that converts 1 µmol of uric acid into allantoin per minute under the operating conditions described: +30 °C ± 1 °C TEA pH 8.9 buffer.
*Ena enota aktivnosti encima (Enzyme Activity Unit - EAU) ustreza encimski aktivnosti, ki spremeni 1 µmol sečne kisline v alantoin na minuto pri določenih pogojih: +30 °C ± 1 °C pufra TEA, pH 8,9.
Special populations Renally or hepatically impaired patients: No dose adjustment is necessary.
Posebna populacija Bolniki z okvaro ledvic ali jeter: Prilagoditev odmerka ni potrebna.
Plasma samples should immediately be prepared by centrifugation in a pre-cooled centrifuge (4°C).
Vzorce plazme morate takoj pripraviti s centrifugiranjem v vnaprej ohlajeni centrifugi (4 °C).
- Allergy/ allergic reactions (rashes and urticaria)
- alergijske reakcije (izpuščaji in urtikarija)
At present, there is insufficient data available on patients being retreated to recommend multiple treatment courses.
Za zdaj je premalo podatkov o bolnikih, ki so jih zdravili ponovno, da bi priporočili ponavljajoče se zdravljenje.
To ensure accurate measurement of uric acid plasma level during treatment with Fasturtec, a strict sample handling procedure must be followed (see section 6.6).
Da bi zagotovili točne meritve ravni sečne kisline v plazmi med zdravljenjem z zdravilom Fasturtec, se morate strogo držati postopka ravnanja z vzorci (glejte poglavje 6.6).
Minimal accumulation of rasburicase (<1.3 fold) was observed between days 1 and 5 of dosing.
Minimalno kopičenje razburikaze (<1,3 kratno) so opazili med 1. in 5. dnevom odmerjanja.
The solvent is a colourless and clear liquid.
Vehikel je brezbarvna in bistra tekočina.
Please tell your doctor if you are taking, or have recently taken, any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Inspect visually prior to use.
Pred uporabo si oglejte raztopino.
Fasturtec is to be used immediately prior to and during the initiation of chemotherapy only, as at the present, there is insufficient data to recommend multiple treatment courses.
Fasturtec uporabljajte le tik pred kemoterapijo ali med njenim začetkom, kajti do zdaj ni dovolj podatkov, da bi priporočili več ponovitev zdravljenja.
Clinical experience with Fasturtec demonstrates that patients should be closely monitored for the onset of allergic-type undesirable effects, especially severe hypersensitivity reactions including anaphylaxis (see section 4.8).
Klinične izkušnje z zdravilom Fasturtec kažejo, da morate bolnike pozorno nadzorovati, da bi opazili začetek alergijskih neželenih učinkov, zlasti hudih preobčutljivostnih reakcij, vključno z anafilakso (glejte poglavje 4.8).
Therefore the reconstituted solution should be diluted under controlled and validated aseptic conditions.
Zato morate rekonstituirano raztopino razredčiti v validiranih aseptičnih pogojih.
(methaemoglobinaemia) - fits (convulsion).
(methemoglobinemija) - krči (konvulzije).
(frequency not known) which may be fatal - low blood pressure (hypotension) - wheezing or difficulty in breathing (bronchospasm) - blood disorders such as a disorder of the blood in which red blood cells are abnormally broken down (haemolysis), destroyed (haemolytic anaemia), or abnormal blood pigment levels
(pogostnost neznana), ki je lahko smrtno nevaren - znižan krvni pritisk (hipotenzija) - sopenje ali težave pri dihanju (bronhospazem) - krvne bolezni, kot je bolezen krvi, pri kateri pride do nenormalne razgradnje rdečih krvnih celic
In order to prevent possible haemolytic anaemia induced by hydrogen peroxide, rasburicase is contraindicated in patients with these disorders.
Da bi preprečili morebitno hemolitično anemijo zaradi vodikovega peroksida, je razburikaza kontraindicirana pri bolnikih s temi okvarami.
The recommended dose is 0.20 mg per kg of body weight per day in both children and adults.
Priporočen odmerek je 0,20 mg na kg telesne mase na dan, tako pri otrocih, kot pri odraslih.
There are no data from the use of rasburicase in pregnant women.
Podatkov o uporabi razburikaze pri nosečnicah ni.
In humans, uric acid is the final step in the catabolic pathway of purines.
Pri človeku je sečna kislina zadnja stopnja katabolne poti purinov.